Mylan is committed to maintaining the highest quality manufacturing standards at its facilities around the world. In support of this commitment, Mylan’s plants are regularly inspected by health authorities to ensure compliance for the various markets we serve. The U.S.
MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH , June 28, 2018 /PRNewswire/ -- Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that the two companies will partner to commercialize a biosimilar to Enbrel® (etanercept).
- Bivalirudin for Injection is an anticoagulant intended for use with aspirin - HERTFORDSHIRE, England and PITTSBURGH , June 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a
On the afternoon of June 13, 2018, we received an update from the U.S. Food & Drug Administration (“FDA”) concerning our pending approval for Generic Advair Diskus® that FDA has identified minor deficiencies to be relayed in a Complete Response Letter on June 27, 2018. Because our Abbreviated New
Award Presented at HDA Business and Leadership Conference STAMFORD, Conn. , June 11, 2018 /PRNewswire/ -- Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Mylan, in recognition of its outstanding commitment to
Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection following myelosuppressive chemotherapy Fulphila is the second FDA-approved biosimilar through the Mylan-Biocon collaboration, further
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , June 1, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON ) today announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical Oncology (
HERTFORDSHIRE, England and PITTSBURGH , June 1, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that CEO Heather Bresch will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA , on Wednesday, June 13, 2018 ,
On May 16, 2018, Mylan N.V. and Mylan Inc., an indirect wholly owned subsidiary of Mylan N.V., delivered notices to The Bank of New York Mellon, as trustee (the “Trustee”), notifying the Trustee of their election to redeem the following series of notes on June 15, 2018 (the “Redemption Date”):
Collaboration aims to demystify STEM and broaden its perceived application Program will leverage 4-H infrastructure and WVU STEM outreach, reaching every county in West Virginia Mylan commits a $5 million charitable contribution over 10 years to empower West Virginia children to be Curious, Active,